RT Journal Article
SR Electronic
T1 A Cascaded Droplet Microfluidic Platform Enables High-throughput Single Cell Antibiotic Susceptibility Testing at Scale
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.25.21259551
DO 10.1101/2021.06.25.21259551
A1 Zhang, Pengfei
A1 Kaushik, Aniruddha
A1 Hsieh, Kuangwen
A1 Li, Sixuan
A1 Lewis, Shawna
A1 Mach, Kathleen E.
A1 Liao, Joseph C.
A1 Carroll, Karen C.
A1 Wang, Tza-Huei
YR 2021
UL http://medrxiv.org/content/early/2021/07/02/2021.06.25.21259551.abstract
AB Single-cell antibiotic susceptibility testing (AST) offers a promising technology by achieving unprecedented rapid testing time; however, its potential for clinical use is marred by its limited capacity for performing AST with scalable antibiotic numbers and concentrations. To lift the one antibiotic condition per device restriction common in single-cell AST, we develop a cascaded droplet microfluidic platform that uses an assembly line design to enable scalable single-cell AST. Such scalability is achieved by executing bacteria/antibiotic mixing, single-cell encapsulation, incubation, and detection in a streamlined workflow, facilitating susceptibility testing of each new antibiotic condition in 2 min after a 90 min setup time. As a demonstration, we test 3 clinical isolates and 8 positive urine specimens against 15 antibiotic conditions for generating antiprograms in ∼2 h and achieve 100% and 93.8% categorical agreement, respectively, compared to laboratory-based clinical microbiology reports which becomes available only after 48 h.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication is financially supported by the National Institutes of Health (R01AI137272, R01AI138978, R01AI117032).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Urine specimens representing uncomplicated UTI were obtained and analyzed under an approved institutional review board (IRB) protocol at the Johns Hopkins University School of Medicine (#IRB00189525).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in Supplementary Material